Conflict of interest
cancer
FOUNDER, CANCER, GASTRIC CANCER, ONCOLOGY, DISEASES
F Lordick reports study funding from Astellas Pharma, Inc.; grants from BMS and MSD (to institution); consulting fees from Amgen, Astellas, AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, MSD, Roche, and Zymeworks; payments or honoraria from Amgen, Astellas, AstraZeneca, BMS, Eli Lilly, MSD, and Roche; travel support from BMS and Roche; advisory board participation for BioNTech; and leadership or fiduciary role in the European Society for Medical Oncology (unpaid) and the International Gastric Cancer Association (unpaid). P Thuss-Patience reports study funding from Astellas Pharma, Inc. and advisory board participation (outside the submitted work) with Lilly, BMS, MSD, Roche, Astellas Merck Serono, Servier, AstraZeneca, and Pfizer. M Bitzer reports study funding from Astellas Pharma, Inc. U Sahin is a co-founder and ex-shareholder of Ganymed Pharmaceuticals AG; he has also received consultancy fees from Ganymed Pharmaceuticals AG; he is also founder, chief executive officer, and a stockholder of BioNTech Holding, which is developing immunotherapies for cancer and other diseases. In addition, he has received consultancy fees from Astellas Pharma, Inc. and has pending, issued, and licensed patents relevant to the work, which have been acquired by Astellas Pharma, Inc. and for which he receives milestone payments. D Maurus reports study funding from Astellas Pharm, Inc. Ö Türeci is co-founder, chief executive officer, and an ex-shareholder of Ganymed Pharmaceuticals AG; she is also co-founder, chief medical officer and a stockholder of BioNTech Holding, which is developing immunotherapies for cancer and other diseases. In addition, she has received consultancy fees from Astellas Pharma, Inc. and has pending, issued, and licensed patents relevant to the work, which have been acquired by Astellas Pharma, Inc. and for which she receives milestone payments. All authors report management support from OPEN Health for manuscript development.